2015-08-21T12:28:01-05:00 2015-03-31 953001179 WINDES INC PO BOX 87 LONG BEACH CA 90801 990 2014-04-01 956043953 ARTHRITIS NATIONAL RESEARCH FOUNDATION ARTH 5624376808 200 OCEANGATE NO 830 LONG BEACH CA 90802 HELENE BELISLE EXECUTIVE DIRECTOR 5624376808 2015-08-18 1 DONITA M JOSEPH P00286656 5624351191 2015-08-05 2014 2016-02-25 16:41:14Z HELENE BELISLE 200 OCEANGATE 830 LONG BEACH CA 90802 2335855 0 X WWW.CUREARTHRITIS.ORG X 1952 CA PROVIDE FINANCIAL SUPPORT FOR: PREVENTION, TREATMENT & CURE OF ARTHRITIS & OTHER RHEUMATIC DISEASES. 16 15 3 50 0 0 990456 1009084 24950 46049 269796 387723 0 0 1285202 1442856 960366 1024562 0 0 237053 254223 0 0 32784 232597 217120 1430016 1495905 -144814 -53049 8580407 8656814 4517 5104 8575890 8651710 TO PROVIDE INITIAL RESEARCH FUNDING TO BRILLIANT, INVESTIGATIVE SCIENTISTS WITH NEW IDEAS TO CURE ARTHRITIS AND RELATED AUTOIMMUNE DISEASES. 0 0 1188519 1024562 EACH YEAR, ARTHRITIS RESEARCH GRANTS ARE AWARDED TO INDEPENDENT M.D. AND/OR PHD SCIENTISTS AT UNAFFILIATED RESEARCH FACILITIES AND UNIVERSITIES ACROSS THE COUNTRY. ANRF'S SCIENTIFIC ADVISORY BOARD PERFORMS A NIH-LEVEL REVIEW OF ALL APPLICATIONS, RANKING THE PROPOSALS AS TO THE EXCELLENCE OF THE SCIENCE, OPPORTUNITY TO MAKE A BREAK-THROUGH DISCOVERY AND THE QUALITY OF THE INVESTIGATOR. AWARDEES, WHO RECEIVE A MAXIMUM GRANT OF $100,000, MUST PROVIDE PROGRESS AND FINAL REPORTS OF THEIR WORK, INCLUDING PUBLICATIONS IN SCIENTIFIC JOURNALS AND PRESENTATIONS AT SCIENTIFIC MEETINGS. IF PROGRESS IS DEEMED SIGNIFICANT IN THE FIRST YEAR, AWARDEES MAY APPLY FOR AND EARN A SECOND YEAR OF SUPPORT. ANRF ALSO SUPPORTS SMALL TRAVEL GRANTS TO SCIENTIFIC MEETINGS FOR YOUNG INVESTIGATORS. 161553 ANRF HAS VARIOUS PROGRAMS TO RAISE AWARENESS WITHIN THE GENERAL PUBLIC, THOSE SUFFERING WITH ARTHRITIS AND THE MEDICAL/SCIENTIFIC RESEARCH COMMUNITIES ABOUT THE IMPORTANCE OF AND NEED FOR ARTHRITIS RESEARCH FOR DEVELOPING A CURE AND MORE EFFECTIVE TREATMENTS. ALSO PART OF THE EDUCATION COMPONENT IS RAISING AWARENESS OF THE PREVALENCE OF ARTHRITIS, THE FACT THAT CHILDREN GET ARTHRITIS AND THE CURRENT WORK BEING DONE IN THE FIELD OF ARTHRITIS RESEARCH. 12908 46049 RACING FOR A CURE IS A SPECIFIC PROGRAM TO RAISE AWARENESS OF THE NEED FOR ARTHRITIS RESEARCH AND RAISE FUNDS TO SUPPORT ANRF'S WORK TO FUND RESEARCH TO CURE ARTHRITIS. RACING FOR A CURE TEAM MEMBERS RACE IN ANY RACE (RUNNING, WALKING, SWIMMING, TRIATHLONS) HELD ANYWHERE IN THE WORLD. THEY ARE LINKED TOGETHER BY THEIR COMMITMENT TO ARTHRITIS RESEARCH. 1362980 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 3 0 1 3 1 0 0 0 0 0 0 0 0 0 0 X 16 15 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA AZ CT IL UT VA FL WA NJ X HELENE BELISLE 5624376808 200 OCEANGATE NO 830 LONG BEACH CA 90802 SHAUN SKERIS PRESIDENT 5.00 X X 0 0 0 SALLY ANNE SHERIDIAN VICE PRESIDENT 1.00 X X 0 0 0 KELLY ROUBA 2ND VICE PRESIDENT 1.00 X X 0 0 0 HELENE BELISLE EXECUTIVE DIRECTOR / SECRETARY 40.00 X X 120000 0 13500 MARK SCHULTEN TREASURER 1.00 X X 0 0 0 KATHRYN S FERRIS DIRECTOR 1.00 X 0 0 0 GALE A GRANGER PHD DIRECTOR 1.00 X 0 0 0 DAVID ISRAELSKY DIRECTOR 1.00 X 0 0 0 KRISTY MCPHERSON DIRECTOR 1.00 X 0 0 0 BRITT MEYER DIRECTOR 1.00 X 0 0 0 LYNN E MOYER DIRECTOR 1.00 X 0 0 0 JAMES ROSE PHARMD DIRECTOR 1.00 X 0 0 0 DEBBIE SAMPSON DIRECTOR 1.00 X 0 0 0 TRAVIS MONTGOMERY DIRECTOR 1.00 X 0 0 0 KATHLEEN TEPLEY DIRECTOR 1.00 X 0 0 0 CARL WARE PHD DIRECTOR 1.00 X 0 0 0 120000 0 13500 1 0 0 0 0 166991 842093 1009084 RACING FOR A CURE 900099 46049 46049 46049 162005 162005 1118717 892999 225718 225718 225718 1442856 46049 0 387723 X 1024562 1024562 138139 114033 14086 10020 55000 45144 5500 4356 38834 32033 4849 1952 5877 4710 728 439 16373 13536 1731 1106 19371 19371 36580 27480 9100 14467 13495 764 208 51151 22126 24243 4782 24393 18475 5418 500 19581 13005 5178 1398 17531 17209 322 6489 1666 4683 140 AWARENESS PROGRAM 24203 13158 3212 7833 RECOGNITION 2806 2048 708 50 DUES AND SUBSCRIPTIONS 548 300 248 1495905 1362980 100141 32784 117 117 771451 456935 56415 56415 7739410 8130333 13014 13014 8580407 8656814 4517 5104 4517 5104 X 8565604 8641424 10286 10286 8575890 8651710 8580407 8656814 -53049 128869 0 X 0 1 X 1 0 X 2162000 1516453 1045622 990456 1009083 6723614 2162000 1516453 1045622 990456 1009083 6723614 2572531 4151083 122024 130143 147635 165869 162005 727676 7451290 95580 0.55710 0.51110 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 4401092 101000 274069 700438 4075723 3993660 2556 405550 674 4401092 3489317 250000 254821 478 3993660 2394531 1000000 95028 242 3489317 2063952 504994 -174224 191 2394531 0.99750 0.00250 0 0 0 X 1571724 128869 128869 1442855 0 1442855 1495904 0 1495904 0 1495904 PART V, LINE 4: AN ENDOWMENT ACCOUNT WAS ESTABLISHED IN FISCAL YEAR 2007-08. THE BOARD OF DIRECTORS CAN, AND HAS MADE THE DECISION TO ADD UNRESTRICTED FUNDS TO THE ENDOWMENT FUND IN ORDER TO GROW THIS FUND SO THAT FUTURE INCOME EARNED MAY BE USED FOR GRANT AWARDS AND ORGANIZATION OPERATIONS, IF NECESSARY. THE ENDOWMENT ACCOUNT IS MANAGED BY MEMBERS OF THE BOARD OF DIRECTORS' FINANCE COMMITTEE. PART X, LINE 2: THE FOUNDATION RECOGNIZES THE FINANCIAL STATEMENT BENEFIT OF TAX POSITIONS, SUCH AS ITS FILING STATUS AS TAX-EXEMPT, ONLY AFTER DETERMINING THAT THE RELEVANT TAX AUTHORITY WOULD MORE LIKELY THAN NOT SUSTAIN THE POSITION FOLLOWING AN AUDIT. THE FOUNDATION IS SUBJECT TO POTENTIAL INCOME TAX AUDITS ON OPEN TAX YEARS BY ANY TAXING JURISDICTION IN WHICH IT OPERATES. THE STATUTE OF LIMITATIONS FOR FEDERAL PURPOSES IS THREE YEARS AND FOR CALIFORNIA PURPOSES IS FOUR YEARS. 1 UNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE 9500 GILMAN DR 0656 LA JOLLA CA 92093 PUBLIC UNIVERSITY 50000 THE NOVEL ROLE OF YAP IN REGULATING SYNOVIOCYTES BEHAVIOR IN RA BRIGHAM & WOMEN'S HOSPITAL SMITH 516A ONE JIMMY FUND WAY BOSTON MA 02115 042103580 501(C)(3) 50000 MODULATING NEUTROPHIL RECRUITMENT INTO THE JOINT FOR ARTHRITIS THERAPY YALE UNIVERSITY 300 GEORGE ST 3RD FL STE 353 NEW HAVEN CT 06520 060646973 PUBLIC UNIVERSITY 100000 BETA2-GLYCOPROTEIN-I CROSS-REACTIVITY WITH GUT COMMENSALS IN ANTIPHOSPHOLIPID SYNDROME STANFORD UNIVERSITY 300 PASTEUR DR EDWARDS BLDG R164 STANFORD CA 94305 941156365 501(C)(3) 50000 THE NOVEL ROLE OF TET1 IN THE ONSET AND DEVELOPMENT OF OSTEOARTHRITIS RHODE ISLAND HOSPITAL 1 HOPPIN ST SUITE 1300 PROVIDENCE RI 02903 050258954 501(C)(3) 100000 ROLE OF CATHEPSIN K+ CHONDROID PROGENITORS IN ARTICULAR CARTILAGE ANTIDEGENERATION HOSPITAL FOR SPECIAL SURGERY 535 E 70TH ST RESEARCH BLDG 4TH FLOOR NEW YORK NY 10021 136714749 501(C)(3) 100000 TNFA MODIFIES FLS CHROMATIN LANDSCAPE TO INDUCE DISEASE STATE UCLA 615 CHARLES E YOUNG DR S LOS ANGELES CA 90095 PUBLIC UNIVERSITY 100000 FUNCTIONAL ASSESSMENT OF ATX/LPA INHIBITORS AND AUTOLOGOUS ARTICULAR CARTILAGE PRECURSORS IN A PIG MODEL OF JOINT INJURY UNIVERSITY OF MICHIGAN 3003 S STATE ST 1ST FLOOR ANN ARBOR MI 48109 PUBLIC UNIVERSITY 179628 EXPLORING THE INFLUENCE OF CUTANEOUS INFLAMMATION ON SYSTEMIC LUPUS ACTIVITY; PRENATAL DIETARY INTERVENTION IMPROVES AGE-ASSOCIATED RHEUMATOID ARTHRITIS UNIVERSITY OF CALIFORNIA SAN FRANCISCO 513 PARNASSUS AVE HSW 1047 SAN FRANCISCO CA 94143 PUBLIC UNIVERSITY 94934 INVESTIGATING THE ROLE OF LINCRNA-COX2 AND RA33 IN INFLAMMATORY ARTHRITIS UNIVERSITY OF TX HEALTH SCIENCE CENTER AT SAN ANTONIO 7703 FLOYD CURL DR SAN ANTONIO TX 78229 PUBLIC UNIVERSITY 100000 COMBINED ESTROGEN RECEPTOR INHIBITORS AND EPIGENETIC MODULATORS AS EFFECTIVE THERAPEUTICS IN LUPUS CLEVELAND CLINIC 9500 EUCLID AVE NC-10 CLEVELAND OH 44195 340714585 501(C)(3) 100000 ROLES OF SOXC TRANSCRIPTION FACTORS IN FIBROBLAST-LIKE SYNOVIOCYTES DURING RHEUMATOID ARTHRITIS 11 PART I, LINE 2: IN MID-JANUARY EACH YEAR, THE ANRF OFFICE RECEIVES APPROXIMATELY 60 TO 70 GRANT APPLICATIONS PER YEAR FROM SCIENTISTS ACROSS THE COUNTRY. APPLICATIONS MUST FOLLOW THE PUBLISHED GRANT GUIDELINES AND POLICIES ESTABLISHED BY THE ANRF. THE SCIENTIFIC ADVISORY BOARD (SAB) CONDUCTS AN NIH-LEVEL REVIEW PROCESS PRIOR TO A REVIEW MEETING SESSION HELD IN MARCH OR APRIL (THE DATE VARIES FROM YEAR TO YEAR, DEPENDING ON THE SCHEDULES OF THE MEMBERS). AT THIS REVIEW MEETING, THE SAB COLLECTIVELY RANKS THE APPLICANTS. THIS RANKING IS PRESENTED AT THE REGULAR BOARD OF DIRECTORS MEETING, GENERALLY HELD WITHIN A COUPLE WEEKS OF THE SAB REVIEW MEETING. AT THIS BOARD MEETING, ANRF MEMBERS REVIEW AND VOTE ON THE ANNUAL BUDGET, INCLUDING THE TOTAL OF GRANT AWARDS FOR THE YEAR, BASED ON THE RANKING AND RECOMMENDATIONS FROM THE SAB. THE ANRF'S LARGEST ANNUAL EXPENSE IS THE COLLECTIVE TOTAL OF RESEARCH GRANTS AWARDED. GRANTS ARE PAID IN TWO INSTALLMENTS DURING THE FISCAL YEAR TO THE GRANTEE'S RESEARCH INSTITUTION. THE FIRST PAYMENT OCCURS ON OR BEFORE JUNE 1 WHEN A CHECK FOR 50% OF THE AWARD IS SENT WHILE THE SECOND PAYMENT OCCURS IN EARLY MARCH OF THE FOLLOWING YEAR ONCE THE ANRF HAS RECEIVED A PROGRESS REPORT WHICH IS APPROVED BY THE CHAIR OF THE SAB. THIS PROGRESS REPORT MUST DEMONSTRATE ADHERENCE TO THE SPECIFIC AIMS OUTLINED IN THE ORIGINAL PROPOSAL AND PROGRESS TOWARD THE GOAL. AT THE END OF THE GRANT AWARD TERM, RECIPIENTS MUST SUBMIT A NARRATIVE, FINAL REPORT, IN WHICH THEY DELINEATE THEIR RESEARCH RESULTS AND LIST PUBLICATIONS OR PUBLIC PRESENTATIONS (GENERALLY AT PROFESSIONAL SCIENTIFIC MEETINGS) THAT THEY HAVE GENERATED AS A RESULT OF THE ANRF GRANT AWARD. DEREK BELISLE FAMILY MEMBER OF HELENE BELISLE 55000 COMPENSATION PAID FOR SERVICES AS AN EMPLOYEE. 0 FORM 990, PART VI, SECTION B, LINE 11 BOTH THE AUDITED FINANCIAL STATEMENTS AND FORM 990 ARE DISTRIBUTED TO THE MEMBERS OF THE BOARD FOR REVIEW. UPON APPROVAL BY THE BOARD OF DIRECTORS THE EXECUTIVE DIRECTOR SIGNS AND RELEASES THESE DOCUMENTS TO THE PUBLIC AND/OR SUBMITS THE DOCUMENTS TO THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C CONFLICTS OF INTEREST ARE MONITORED CONSTANTLY THROUGH AN ANNUAL WRITTEN CONFIRMATION THAT IS COMPLETED AND SUBMITTED BY ALL BOARD MEMBERS. ADDITIONALLY, ANY POSSIBLE INDICATION OF CONFLICT OF INTERESTS THAT ARE BROUGHT TO THE ATTENTION OF THE BOARD, BOARD MEMBERS, SAB MEMBERS OR THE EXECUTIVE DIRECTOR ARE FURTHER REVIEWED BY THE AUDIT COMMITTEE CHAIR TO DETERMINE WHETHER OR NOT A CONFLICT OF INTEREST EXISTS. THE ANRF IS VIGILANT IN ITS POLICIES WITH REGARDS TO CONFLICT OF INTEREST. AFTER REVIEW BY THE AUDIT COMMITTEE CHAIR, IF THERE ARE REMAINING QUESTIONS AS TO A CONFLICT OF INTEREST, THE ANRF'S COUNSEL WOULD BE CONTACTED AND THE MATTER BROUGHT UP TO ALL INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS THAT WOULD MAKE THE FINAL DETERMINATION AS TO WHETHER OR NOT A CONFLICT EXISTS. FORM 990, PART VI, SECTION B, LINE 15 THE FINANCE COMMITTEE WORKED WITH AN ADVISORY BOARD MEMBER WHO IS AN EXPERT IN HUMAN RESOURCES FOR THE PURPOSES OF DETERMINING COMPENSATION OF THE EXECUTIVE DIRECTOR. TOGETHER THEY FORMED A COMPENSATION COMMITTEE. THIS INCLUDED REVIEW OF COMPARABLE COMPENSATION FOR COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS AND AN ONLINE SALARY REVIEW COMPLETED BY EVERY BOARD AND ADVISORY BOARD MEMBER, TALLIED BY COMPENSATION COMMITTEE. THIS PROCESS WAS FOLLOWED FOR FISCAL YEAR 2013-14 AND 2014-15. FORM 990, PART VI, SECTION C, LINE 19 ALL REQUESTS FOR THE 990, FORM 1023, AND ORGANIZATIONAL DOCUMENTS SUCH AS FINANCIAL STATEMENTS, CONFLICTS OF INTEREST POLICY, AND GOVERNING DOCUMENTS WILL BE SENT OUT BY REQUEST VIA REGULAR MAIL OR E-MAIL. PART IX, LINE 6 & SCHEDULE L PARTS IV AND V DEREK BELISLE IS A FAMILY MEMBER OF THE EXECUTIVE DIRECTOR. DEREK'S COMPENSATION IS DETERMINED BY A BOARD COMMITTEE BASED UPON AN INDEPENDENT COMPENSATION SURVEY AS WELL AS PERIODIC REVIEWS AND INTERVIEWS. FORM 990, PART VII HELENE BELISLE IS THE TOP MANAGEMENT OFFICER WITHIN THE ORGANIZATION. MARK SHULTEN IS THE TOP FINANCIAL OFFICER WITHIN THE ORGANIZATION.